Healing & Recovery — Category Comparisons
Published · Researched 2026-09-21
Track: Healing & Recovery peptides | Research date: 2026-09-20/21 | Items: 14 All prices observed 2026-09-20 unless noted. Per-item dossier files for this category are included in the research library. Not medical advice. Research documentation only; none of these products are approved for human use.
1. Specs head-to-head
| Item | Identity | Molecular weight | Typical vial sold | Regulatory status |
|---|---|---|---|---|
| BPC-157 | 15-aa peptide (GEPPPGKPADDAGLV) | 1,419.53 Da | 10 mg | Research chemical — NOT FDA/EMA approved. Was FDA compounding Category 2 (Sep 2023), removed Apr 2026. |
| TB-500 (Thymosin Beta-4 fragment) | 7-aa fragment (Ac-LKKTETQ, residues 17–23 of TB-4) | ~889 Da (UNVERIFIED exact) | 5 mg | Research chemical — NOT FDA/EMA approved. Removed from FDA Category 2 (Apr 15, 2026). WADA S2 banned. |
| GHK-Cu (injectable) | Copper tripeptide complex (Gly-His-Lys + Cu²⁺) | 403.9 Da (complex) | 50 mg | Injectable: research chemical, NOT approved. Topical GHK-Cu is an established cosmetic ingredient (different use, different safety picture). |
| KPV | 3-aa α-MSH fragment (Lys-Pro-Val) | 342.43 Da | 10 mg | Research chemical — NOT FDA/EMA approved. FDA: insufficient data to assess harm. |
| ARA-290 (Cibinetide) | 11-aa EPO-derived peptide | ~1,257 Da (UNVERIFIED exact) | 10 mg | Research chemical — NOT approved. Developed by Araim Pharma, reached Phase 2 for neuropathy (investigational, not approval). |
| IGF-1 LR3 | 83-aa IGF-1 analogue | ~9,111 Da | 1 mg | Research chemical — NOT FDA/EMA approved. WADA explicitly names Long R3 IGF-1 under S2. |
| IGF-1 DES | 67-aa truncated IGF-1 analogue | ~7,371 Da | 1 mg | Research chemical — NOT FDA/EMA approved. WADA S2 banned (all IGF-1 analogues). |
| MGF | 24-aa C-terminal IGF-1 splice fragment | ~2,867 Da | 2 mg | Research chemical — NOT FDA/EMA approved. WADA S2 banned (explicitly named). |
| PEG-MGF | 24-aa MGF core + PEG chain | UNVERIFIED (vendor pages inconsistent) | 2 mg | Research chemical — NOT FDA/EMA approved. WADA S2 banned (MGF covered). |
| BPC-157 Arginate Salt | Same 15-aa sequence, di-L-arginine salt | Parent ~1,419 Da (UNVERIFIED exact salt mass) | UNVERIFIED (marketed mostly as oral caps/nasal) | Research chemical — NOT FDA/EMA approved in any salt form. |
| BPC-157 + TB-500 blend ("Wolverine stack") | Pre-mixed BPC-157 + TB-500 fragment in one vial | 1,419 + ~889 Da | 10 mg (5+5) or 20 mg (10+10) blend | Gray-market blend — NOT a registered product. Both components unapproved. WADA: TB-4 fragments banned. |
| Thymosin Beta-4 (full-length) | 43-aa native protein (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) | ~4,963.44 Da | 2–10 mg | Research chemical — NOT FDA/EMA approved. Recombinant TB4 (RegeneRx RGN-352/RGN-259) reached Phase I/II for cardiac/ocular/dermal use (investigational). |
| Pentosan Polysulfate Sodium | NOT a peptide — semi-synthetic sulfated polysaccharide (beechwood xylan ester), ~5,700 Da | ~5.7 kDa avg | Vet vial 7.5 mL @ 250 mg/mL | Approved drug in specific forms: oral Elmiron (interstitial cystitis, US); veterinary injectable FDA-approved for horses (Zycosan); registered for dogs (Cartrophen/Zydax, AU/CA). Compounded human injectable = prescription-gated gray zone. |
| LL-37 | 37-aa human cathelicidin antimicrobial peptide | ~4,493 Da | 5 mg | Research chemical — NOT FDA/EMA approved. Human data limited to early wound-healing/antimicrobial studies. |
Half-life is UNVERIFIED for every item (no human PK data in the gray market). Community-quoted figures (e.g. TB-500 ~5 h, PEG-MGF ~48 h) are forum claims, not data.
2. Value-for-money
Typical observed street price (2026-09-20), per-mg bands, and the community's verdict on worth.
| Item | Observed street band | Approx. $/mg | Community-valued factors | Value verdict |
|---|---|---|---|---|
| BPC-157 (10 mg) | $23–$65 (PureRx → Luxe) | ~$2.30–$6.50 | Social-validation density (Tier 1); recovery anecdotes; vendor competition | Category value winner (peptides) — deepest anecdotal base, most competitive pricing, 3x+ spread rewards shopping |
| TB-500 (5 mg) | $44.99–$66 | ~$9–$13 | Synergy with BPC-157 (the pair is the community's default); 3–4 week anecdote timelines | Fair value as the pair's second half; poor value alone (effect hard to isolate) |
| GHK-Cu (50 mg) | $29–$64 | ~$0.58–$1.30 | Cheapest compound per mg; hair/skin anecdote volume | Cheapest per mg in the category — but injectable evidence is the thinnest of any Tier 1 item |
| KPV (10 mg) | $38.24–$60 (US); €29.99 EU | ~$3.80–$6.00 | Well-articulated anti-inflammatory mechanism; MCAS/gut niches | Reasonable niche pick; thin vendor field |
| ARA-290 (10 mg) | $49.99 (single vendor found) | ~$4–$5 | Only item with human RCT data (Phase 2); defined receptor mechanism | Credible but illiquid: one observed vendor = no price competition |
| IGF-1 LR3 (1 mg) | $48.75 (new-customer) – $160 | ~$49–$160 | Large multi-year experience trail; pump/recomp/recovery | Expensive per mg; veterans say muscle-mass payoff is modest — hypoglycemia risk is the real cost |
| IGF-1 DES (1 mg) | $80–$110 | ~$80–$110 | Believed-localized action (connoisseur pick vs LR3) | Premium for a belief the community itself flags as "working theory" |
| MGF (2 mg) | $10–$30 (GiantLab $10 outlier) | ~$5–$15 | Budget entry; post-workout localized-use lore | Budget winner on paper — offset by reconstituted fragility everyone agrees on |
| PEG-MGF (2 mg) | $40–$50 (SigmaLabsUS $21.25 outlier) | ~$20–$25 | Pegylation = longer activity (theoretically) | 2–4x the price of plain MGF for a modification the community has argued about since 2006 |
| BPC-157 Arginate | UNVERIFIED (no current vial listing) | — | Oral/nasal stability rationale (patent-backed) | Cannot be value-ranked; injectable consensus = no advantage over acetate |
| Wolverine stack (10–20 mg blend) | $68–$120 (Real Peptides $68, Guardian Labs $80/20 mg, Pacific Edge $79.95/20 mg, Everest $119.99/20 mg) | ~$3.40–$6.00 | One-vial convenience; community's default protocol | Convenience tax + QC risk: a Sept 2026 Threads post showed a blend vial failing identity testing — separate vials + COA is the experienced-user recommendation |
| Thymosin Beta-4 full-length | $37.25–$175 (2–5 mg) | ~$18.6–$35 | The molecule with actual human clinical history | Overpriced trap — $175/5 mg vs ~$55 TB-500 when gray-market labels blur the two and COAs rarely prove which you got |
| Pentosan Polysulfate | Vet vial $90–$115 (Zycosan 7.5 mL); compounded human injectable ~$250 (Regen Doctors, RWA Center); Cartrophen ~$30/injection vet-reported (AU) | — | Veterinary standard for osteoarthritis; biohacker joint-degeneration niche ranks it above BPC/TB-500 | Real drug, real supply chain — but human injectable supply is prescription-gated and expensive; vet-sourced use carries obvious sourcing-risk flags |
| LL-37 (5 mg) | $75 (US); €65.03 (EU); community-catalog ~$99/5 mg (lab-reagent $234–$363/5 mg) | ~$15–$20 | Real antimicrobial/wound-healing literature; infection-specific use | Fair niche pricing; not a general-recovery buy |
Used-market value retention: N/A across the entire category. Facebook Marketplace search returned 0 peptide results — there is no resale market for research chemicals. Nothing to retain value; nothing to buy used.
Overpriced traps (community consensus):
- Full-length TB-4 at 3x TB-500 prices with no sequence-level identity proof on the COA.
- Pre-mixed Wolverine blends priced above the two vials bought separately, with higher counterfeit/QC risk.
- PEG-MGF's 2–4x premium over plain MGF for a modification never validated in community use.
- BPC-157 arginate oral/nasal products marketed on "1,000× more stable" claims with no peer-reviewed backing.
3. Social sentiment matrix
Qualitative verdicts + the reason. Member/follower counts are observed, not invented; popularity is stated qualitatively throughout.
| Item | Threads | Facebook Groups | Facebook Pages | |
|---|---|---|---|---|
| BPC-157 | Hot — sourcing questions constant; QC/watchdog posts (failed blend vial, Sep 2026) | Strong — beginner dosing questions dominate ("Peptides — information. Education. and sharing", "Peptide Community 101") | Very hot — creator testimonials (Breedlove, Dr. Nykiel, Marji reels), split comments (believers vs placebo skeptics) | Viral — Tai Lopez reel (13K likes, 570 comments) became a sourcing hub |
| TB-500 | Hot — Wolverine-stack sourcing threads; 33-reply shoulder-pain post | Strong — paired with BPC-157 in beginner questions | Hot — owner testimonials, usually bundled in stack content | Strong — spillover from BPC-157 viral content |
| GHK-Cu | Engaged — expectation-management posts (57–86 likes): "2 weeks in, give me a pep talk" | Moderate — appears in GLOW-stack (GHK-Cu/KPV/BPC) discussions | Hot — looksmax/hair-loss owner content, before/after threads | Moderate — brand-page cosmetic framing |
| KPV | Curious — "what to expect" posts; viral harm-reduction explainer (95 likes) | Thin — little observed group signal | Moderate — stack-explainer content | Weak — no notable page signal |
| ARA-290 | Silent | Silent | Silent | Silent — discussion lives on Reddit/forums/Substack (Tier 3) |
| IGF-1 LR3 | Thin — signal dominated by Reddit/r/steroids megathreads instead | Weak observed | Weak observed — forum culture, not visual culture | Weak |
| IGF-1 DES | Silent | Silent | Silent — durable forum distinction (localized vs systemic) lives on boards | Silent |
| MGF | Silent | Silent | Silent — 2006–2026 forum archive is the community | Silent |
| PEG-MGF | Silent | Silent | Silent — decade-long forum argument, never settled | Silent |
| BPC-157 Arginate | Silent | Silent | Silent — niche forum posts on the salt distinction only | Silent |
| Wolverine stack | Hot — blend sourcing + the failed-QC post that spooked the blend format | Strong — the default protocol new users ask about | Hot — stack testimonial reels | Strong — viral BPC-157 content spills over |
| Thymosin Beta-4 (full-length) | Weak — community says "TB-500" and means the fragment | Weak — labeling confusion (vendors sell TB-4 as "TB-500") | Weak | Weak |
| Pentosan Polysulfate | Weak | Weak on FB — strong on bodybuilding forums (MESO-Rx, ProfessionalMuscle) | Weak | Weak |
| LL-37 | Weak observed | Weak observed — biohacker influencer/media layer (Jay Campbell, Dr. Joy Kong) instead | Moderate — practitioner/influencer explainers | Weak |
Cross-Meta read: the social layer splits the category in two. The injury-recovery triad (BPC-157, TB-500, Wolverine stack) + GHK-Cu live on Meta platforms with real owner content. The growth-factor cluster (IGF-1 LR3/DES, MGF, PEG-MGF) and the niche compounds (ARA-290, arginate, full-length TB-4, pentosan, LL-37) live on forums, long-form guides, and influencer media — a different, older internet.
4. Use-case fit & risk matrix
| Item | Best for (community use-case) | Worst for | Failure modes (community-reported) | Support risk |
|---|---|---|---|---|
| BPC-157 | Tendon/ligament/gut complaints in the anecdote record | Anyone wanting clinical evidence; tested athletes (WADA-adjacent risk profile debated) | Underfilled/fake vials (identity-test failures); placebo debate; supplier spam | Low–medium: deep vendor field, Janoshik-COA culture, but 3x price spread and counterfeit blends |
| TB-500 | Paired systemic use with BPC-157 | Solo use (effect hard to isolate); tested athletes (WADA S2 explicit) | Fragment-vs-full-length mislabeling; blend QC failures | Medium: labeling confusion is the standing complaint |
| GHK-Cu | Skin/hair cosmetic experimentation (topical has real history) | Injectable use expecting fast results (community: "takes a while") | Expectation mismatch (slow build); injectable long-term safety unknown | Low (cheap, many vendors) but evidence-poor for injectable route |
| KPV | Anti-inflammatory/gut/MCAS niches | Anyone wanting a large user base to learn from | Small footprint = thin troubleshooting knowledge; formula discrepancy across vendors (C₁₆ vs C₁₉ listings) | Medium: few vendors, thin community |
| ARA-290 | Evidence-minded self-experimenters (only RCT-backed item) | Anyone wanting vendor choice or a big community | Sparse vendor coverage; temporary-feeling effects reported; wrong-sequence vendor listings documented | High: single observed vendor |
| IGF-1 LR3 | Recomp/pump/recovery in the bodybuilding-adjacent crowd | Hypoglycemia-unaware users; tested athletes (WADA named) | Hypoglycemia — the community's #1 signature risk; modest mass payoff vs hype | Low–medium: established gray-market SKU |
| IGF-1 DES | The "trained muscle" localized-use belief | Anyone wanting the belief validated (community flags it as working theory) | Same class risks as LR3; thinner evidence and vendor field | Medium |
| MGF | Budget post-workout localized lore | Anyone expecting stability (fragile once reconstituted — universal agreement) | Degradation in solution; the never-settled PEG debate | Low (cheap) but legacy-SKU availability |
| PEG-MGF | Rest-day systemic-use pattern believers | Skeptics of pegylation (large camp); budget buyers | Inconsistent MW/CAS on vendor pages; "ruined the molecule" camp | Medium: divisive, mid-price |
| BPC-157 Arginate | Oral/nasal experimenters (stability rationale) | Injectable users (consensus: no advantage over acetate) | Marketing outruns evidence ("1,000× stable" unbacked); no current vial pricing | High: niche formats, thin data |
| Wolverine stack | Convenience buyers wanting the default protocol | QC-conscious users (failed identity test Sep 2026); ratio-control purists | Blend counterfeit risk; can't verify component ratios without full COA | Medium-high: convenience vs verifiability tradeoff |
| Thymosin Beta-4 (full-length) | Buyers who specifically want the clinically-investigated molecule | Anyone assuming the label means full-length (vendors blur with TB-500) | Label/sequence ambiguity — experience can't be attributed to either molecule | High: identity is the whole problem |
| Pentosan Polysulfate | Joint-degeneration cases where vet/Rx channels are accessible | Anyone expecting a peptide (it isn't one); Rx-gated buyers without access | Prescription gating; vet-sourcing risk; not a peptide — category mismatch confusion | Medium: real drug supply chain, but human injectable access is the bottleneck |
| LL-37 | Infection/wound-specific experimentation | General recovery use (community: it's not that); the pro-inflammatory edge cases | Cytotoxicity notes from literature; discussed cautiously even by enthusiasts | Medium: fair pricing, but cautious community |
Marketplace parts evidence: none. No "for parts / not working" listings exist — peptides have no secondary market, so the physical-failure-mode signal that Marketplace provides in other categories is absent here. The equivalent signal is third-party COA failures (Janoshik identity/purity fails), which the community treats as the QC layer.
Headline takeaways
- The category has two internets. Meta platforms (Threads/IG/FB) carry the injury-recovery conversation (BPC-157, TB-500, blends, GHK-Cu); forums and long-form media carry the growth-factor and niche compounds. An item's absence from Meta is a signal about its audience, not necessarily its merit — but Tier 3 items demand more skepticism, not less.
- No human clinical evidence exists for any gray-market peptide here — except ARA-290 (Phase 2, investigational) and recombinant full-length TB-4 (Phase I/II, investigational). Everything else runs on anecdote + rodent literature. The community's own QC culture (Janoshik COAs, watchdog posts) is the de facto safety layer, and it only covers identity/purity — not safety.
- The Wolverine stack is the default protocol and the default risk. Convenience blends are where the counterfeit/QC failures show up (Sept 2026 failed-identity post). Experienced users buy separate vials with COAs.
- WADA bans are real and explicit for TB-500/TB-4, IGF-1 (LR3 named), and MGF — tested athletes are playing with eligibility, not just health.
- The honest value ranking: BPC-157 (deepest base, competitive market) → GHK-Cu (cheapest $/mg, thinnest injectable evidence) → TB-500 (only as the pair's second half) → niche picks (KPV, LL-37, ARA-290, pentosan) for specific use-cases → growth factors (expensive, modest payoff, hypoglycemia risk) → traps (full-length TB-4 premium, blends over separate vials, PEG-MGF premium, arginate marketing).
- Pentosan is the category's odd one out and its most "real" drug — approved veterinary forms, a genuine osteoarthritis record — but it is not a peptide, and human injectable access is the whole ballgame.
Social-pulse summary
Dominant: BPC-157 owns the category's social mindshare — Threads sourcing threads, IG creator testimonials, a viral Facebook reel, and active FB Group beginner traffic. TB-500 rides with it as the inseparable pair; the Wolverine blend is the community's default protocol name.
Strong but split: GHK-Cu — high visibility (looksmax/hair-loss IG, expectation-management Threads posts) with an active skeptic camp noting the injectable evidence gap.
Niche-credible: KPV (curiosity + a viral harm-reduction explainer), LL-37 (influencer/practitioner layer, cautious tone), ARA-290 (evidence-minded forum corner, no Meta presence), pentosan (bodybuilding-forum veteran pick).
Forum-native: IGF-1 LR3/DES, MGF, PEG-MGF — decades of board discussion, near-zero Meta footprint.
Overhyped calls: full-length TB-4 sold at 3x TB-500 prices into a labeling blur; pre-mixed blends marketed as premium convenience after a public QC failure; BPC-157 arginate's stability marketing; PEG-MGF's unresolved premium.
Where consensus is strong: separate vials + COAs over blends; GHK-Cu takes months not weeks; MGF is fragile once reconstituted; hypoglycemia is LR3's signature risk. Where it's split: placebo vs effect for BPC-157; whether PEG ruined MGF; whether DES acts locally.
Report index
Research files (14):
- bpc-157 — BPC-157 (Tier 1)
- tb-500 — TB-500 fragment (Tier 1)
- ghk-cu — GHK-Cu injectable (Tier 1)
- wolverine-stack — BPC-157 + TB-500 blend (Tier 1)
- kpv — KPV (Tier 2)
- ll-37 — LL-37, social-pulse pick (Tier 2)
- pentosan-polysulfate — Pentosan Polysulfate Sodium, NOT a peptide (Tier 2)
- thymosin-beta-4 — Thymosin Beta-4 full-length (Tier 2; pure full-length distinction Tier 3)
- igf-1-lr3 — IGF-1 LR3 (Tier 2)
- igf-1-des — IGF-1 DES (Tier 2)
- mgf — MGF (Tier 2)
- peg-mgf — PEG-MGF (Tier 2)
- ara-290 — ARA-290 / Cibinetide (Tier 3)
- bpc-157-arginate — BPC-157 Arginate Salt (Tier 3)
Images (71 total, all verified real photos, JPEG, no reuse across views/items):
- bpc-157: 8 | tb-500: 4 | ghk-cu: 6 | kpv: 6 | ara-290: 6 | igf-1-lr3: 2 | igf-1-des: 6 | mgf: 3 | peg-mgf: 4 | bpc-157-arginate: 3 | wolverine-stack: 5 | thymosin-beta-4: 6 | pentosan-polysulfate: 6 | ll-37: 6
- 8 candidate images were rejected in review (AI/synthetic-looking renders, wrong product, mislabeled vials).
Sources: research notes from the central Threads/FB sweep; this comparison.
Not medical advice. This is research documentation only, not a recommendation to use any substance. The peptide products covered are sold as research chemicals not intended for human use.
Named sources
- Breedlove — | BPC-157 | Hot — sourcing questions constant; QC/watchdog posts (failed blend vial, Sep 2026) | Strong — beginner dosing questions dominate ("Peptides — information.
- Dr. Nykiel — | BPC-157 | Hot — sourcing questions constant; QC/watchdog posts (failed blend vial, Sep 2026) | Strong — beginner dosing questions dominate ("Peptides — information.
- Marji — | BPC-157 | Hot — sourcing questions constant; QC/watchdog posts (failed blend vial, Sep 2026) | Strong — beginner dosing questions dominate ("Peptides — information.
- Tai Lopez reel — | BPC-157 | Hot — sourcing questions constant; QC/watchdog posts (failed blend vial, Sep 2026) | Strong — beginner dosing questions dominate ("Peptides — information.
Source URLs were not recorded for these references.